This is may not be entirely technical question but rather a academic question. But the technique behind the application is within the scope of bioinformatics. So I would try to ask here that:
In each cancer type, there have been tons of papers that describe RNA-Seq based subtyping resulting in molecularly distinct subgroups with survival difference. However, only very few of them gained acceptance at clinical setting, such as breast cancer (luminal subtype A, luminal subtype B, normal breast-like subtype, HER-2 overexpression subtype and basal-like subtype).
My question is: why did this molecular subtyping of breast cancer gain much acceptance but not others? Did this one own some advantages that other did not?